GlassScriptPhysician profile
Raul Alonso
NPI 1194794438
$5,746.15
in general payments reported to CMS, 2019-2025
12 companies · $842 in 2025
The $842 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,176 · 2020: $469 · 2021: $930 · 2022: $869 · 2023: $926 · 2024: $533 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,301.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $3,196.23 | 2019-2023 | Acticor 7 Vr-T Dx, Biomonitor |
| Abbott Laboratories | $2,095.38 | 2023-2025 | Aveir, Gallant, Jot Dx |
| Novartis Pharmaceuticals Corporation | $211.39 | 2019-2022 | |
| Abbvie INC. | $72.46 | 2022 | |
| Janssen Pharmaceuticals, INC | $63.39 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $23.56 | 2023 | Inpefa |
| Baxter Healthcare | $23.26 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| E.R. Squibb & Sons, L.L.C. | $19.09 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $16.41 | 2019 | |
| Pfizer INC. | $12.82 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.16 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raul Alonso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.